Use of Lipid-Lowering Agents for the Prevention of Age-Related Macular Degeneration: A Meta-Analysis of Observational Studies

REFERENCES

• Kahn H A, Leibowitz H M, Ganley J P, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977; 106(1)17–32
   PubMed Web of Science ®Google Scholar
• http://www.cnib.ca/vision-health/vision-loss/amd/index.html CNIB. Spotlight on AMD. In: Canadian National Institute for the Blind, 2006
   Google Scholar
• Guymer R H, Chiu A W, Lim L, et al. HMG CoA reductase inhibitors (statins): Do they have a role in age-related macular degeneration?. Surv Ophthalmol 2005; 50(2)194–206
   PubMedGoogle Scholar
• Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001; 108(4)697–704
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Jensen S C, et al. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997; 104(1)7–21
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of the Census: 1998 Population Estimates; 1998
   Google Scholar
• Congdon N, O'Colmain B, Klaver C C, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol . 2004; 122(4)477–485
   PubMed Web of Science ®Google Scholar
• Klaver C C, Assink J J, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001; 42(10)2237–2241
   PubMedGoogle Scholar
• Friedman D S, O'Colmain B J, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol . 2004; 122(4)564–572
   PubMed Web of Science ®Google Scholar
• McCarty C A, Mukesh B N, Fu C L, et al. Risk factors for age-related maculopathy: The Visual Impairment Project. Arch Ophthalmol . 2001; 119(10)1455–1462
   PubMedGoogle Scholar
• VanNewkirk M R, Nanjan M B, Wang J J, et al. The prevalence of age-related maculopathy: The Visual Impairment Project. Ophthalmology. 2000; 107(8)1593–1600
   PubMedGoogle Scholar
• Mitchell P, Wang J J, Smith W, et al. Smoking and the 5-year incidence of age-related maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol . 2002; 120(10)1357–1363
   PubMedGoogle Scholar
• The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992; 110(12)1701–1708
   PubMedGoogle Scholar
• Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107(12)2224–2232
   PubMed Web of Science ®Google Scholar
• Vinding T, Appleyard M, Nyboe J, et al. Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol . 1992; 70(1)66–72
   Google Scholar
• Cho E, Hung S, Willett W C, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 2001; 73(2)209–218
   PubMed Web of Science ®Google Scholar
• Mares-Perlman J A, Brady W E, Klein R, et al. Dietary fat and age-related maculopathy. Arch Ophthalmol. 1995; 113(6)743–748
   PubMedGoogle Scholar
• Hyman L, Schachat A P, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol. 2000; 118(3)351–358
   PubMedGoogle Scholar
• Seddon J M, Cote J, Davis N, et al. Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003; 121(6)785–792
   PubMedGoogle Scholar
• Vingerling J R, Dielemans I, Bots M L, et al. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995; 142(4)404–409
   PubMedGoogle Scholar
• Curcio C A, Millican C L, Bailey T, et al. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Visual Sci . 2001; 42(1)265–274
   PubMed Web of Science ®Google Scholar
• Farkas T G, Sylvester V, Archer D, et al. The histochemistry of drusen. Am J Ophthalmol . 1971; 71(6)1206–1215
   PubMedGoogle Scholar
• Hageman G S, Mullins R F, Russell S R, et al. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. Faseb J. 1999; 13(3)477–484
   PubMedGoogle Scholar
• Mullins R F, Russell S R, Anderson D H, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 2000; 14(7)835–846
   PubMed Web of Science ®Google Scholar
• Anderson D H, Mullins R F, Hageman G S, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002; 134(3)411–431
   PubMed Web of Science ®Google Scholar
• Ambati J, Ambati B K, Yoo S H, et al. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003; 48(3)257–293
   PubMed Web of Science ®Google Scholar
• Niculescu F, Rus H G, Porutiu D, et al. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis 1989; 78(2–3)197–203
   PubMedGoogle Scholar
• Niculescu F, Rus H G, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65(1–2)1–11
   PubMedGoogle Scholar
• Babaev V R, Dergunov A D, Chenchik A A, et al. Localization of apolipoprotein E in normal and atherosclerotic human aorta. Atherosclerosis 1990; 85(2–3)239–247
   PubMedGoogle Scholar
• Reblin T, Meyer N, Labeur C, et al. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis. 1995; 113(2)179–188
   PubMedGoogle Scholar
• Stary H C, Chandler A B, Dinsmore R E, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92(5)1355–1374
   PubMed Web of Science ®Google Scholar
• The Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934)1383–1389
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326)7–22
   PubMed Web of Science ®Google Scholar
• Brown G, Albers J J, Fisher L D, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323(19)1289–1298
   PubMed Web of Science ®Google Scholar
• The Multicentre Anti-Atheroma Study Group. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344(8923)633–638
   PubMedGoogle Scholar
• Pruefer D, Scalia R, Lefer A M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arteriosclerosis, Thromb Vasc Biol. 1999; 19(12)2894–2900
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103(15)1933–1935
   PubMed Web of Science ®Google Scholar
• Kuvin J T, Karas R H. The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. Curr Opin Cardiol 2003; 18(4)295–300
   PubMedGoogle Scholar
• Li J J, Chen X J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Cor Art Dis 2003; 14(4)329–334
   PubMedGoogle Scholar
• Green W R, Key S N, 3rd. Senile macular degeneration: A histopathologic study. Trans Am Ophthalmol Soc 1977; 75: 180–254
   PubMedGoogle Scholar
• Plenge J K, Hernandez T L, Weil K M, et al. Simvastatin lowers C-reactive protein within 14 days:An effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002; 106(12)1447–1452
   PubMed Web of Science ®Google Scholar
• Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, Thromb Vasc Biol. 2003; 23(1)58–63
   PubMed Web of Science ®Google Scholar
• Lopez P F, Sippy B D, Lambert H M, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. InvestOphthalmol Vis Sci. 1996; 37(5)855–868
   PubMed Web of Science ®Google Scholar
• Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefe's Arch Clin Exper Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1997; 235(5)313–319
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Tomany S C, Wang J J, et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology. 2004; 111(6)1169–1175
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Vingerling J R, Hofman A, et al. Cholesterol lowering drugs and risk of age related maculopathy: Prospective cohort study with cumulative exposure measurement. BMJ (Clinical Research Ed. 2003; 326(7383)255–256
   PubMedGoogle Scholar
• Klein R, Klein B E, Jensen S C, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119(9)1354–1359
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Tomany S C, et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol. 2003; 121(8)1151–1155
   PubMedGoogle Scholar
• Tan J S, Mitchell P, Rochtchina E, et al. Statins and the long-term risk of incident age-related macular degeneration: The Blue Mountains Eye Study. Am J Ophthalmol 2007; 143(4)685–687
   PubMed Web of Science ®Google Scholar
• Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, et al. HEpiMA: Software for the identification of heterogeneity in meta-analysis. Comp Meth Prog Biomed. 2001; 64(2)101–107
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3)177–188
   PubMedGoogle Scholar
• Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150(2)206–215
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin R esEd.) 1997; 315(7109)629–634
   PubMed Web of Science ®Google Scholar
• Friedman E, Rigas I K, Makar M. The relationship of statin use to the development of age-related macular degeneration. IOVS 2005; 46: 199, (Suppl. S)
   Web of Science ®Google Scholar
• McGwin G, Jr., Owsley C, Curcio C A, et al. The association between statin use and age related maculopathy. Br J Ophthalmol. 2003; 87(9)1121–1125
   PubMedGoogle Scholar
• McGwin G, Jr., Modjarrad K, Hall T A, et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol 2006; 124(1)3–37
   Google Scholar
• McGwin G, Jr., Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology. 2005; 112(3)488–494
   PubMed Web of Science ®Google Scholar
• Smeeth L, Cook C, Chakravarthy U, et al. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol. 2005; 89(9)1171–1175
   PubMedGoogle Scholar
• McCarty C A, Mukesh B N, Guymer R H, et al. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Australia 2001; 175(6)340
   PubMedGoogle Scholar
• Hall N F, Gale C R, Syddall H, et al. Risk of macular degeneration in users of statins:Cross sectional study. BMJ (Clinical Research Ed. 2001; 323(7309)375–376
   PubMedGoogle Scholar
• Delcourt C, Michel F, Colvez A, et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: The POLA study. Ophthal Epidemiol 2001; 8(4)237–249
   PubMedGoogle Scholar